Yahoo Web Search

Search results

1. www.genmab.comWelcome to Genmab

   www.genmab.com

   • Cached

   Genmab is a leading biotech company that develops and commercializes antibody medicines for cancer and other serious diseases. Learn about their products, science, partnerships, investors, news and career opportunities.

   • Careers

     “Genmab is a science-driven company,” Barbara says. “We’re...

   • Pipeline

     Genmab is developing innovative antibody-based therapeutics...

     Antibody Technology Platforms

     · About

   • Transforming The Future of Antibody-Based Cancer Treatment

     Genmab, our. medicines, research findings, and more. Genmab...

     Check out our history

     · Take a peek at the future

     · Join our mission

     · Sign Up

     · Compliance and Disclosures

     · Legal Notice

   • Investors

     Founded in Copenhagen, Denmark in 1999, Genmab A/S’s...

   • Executive Committee

     Mr. Pagano joined Genmab in 2007, was appointed Senior Vice...

   • Who We Are

     Our core purpose summarizes what we strive for – our...

     History

     · Board of Directors

   • Medicines

     We would like to show you a description here but the site...

   • Partnering

     In June 2021, Genmab and Bolt entered into an oncology...

   • Media

     Media Innovation makes news. When you have a passion for...

   • Locations

     Genmab US, Inc. 777 Scudders Mill Road Plainsboro, NJ 08536...

2. en.wikipedia.org › wiki › GenmabGenmab - Wikipedia

   en.wikipedia.org › wiki › Genmab

   • Cached

   Genmab's technology is licensed from Medarex to create fully human high affinity antibodies using transgenic mice. These antibodies are less likely to elicit an allergic reaction and other side effects compared with other types of man-made antibodies containing other animal proteins because the IgG antibodies produced have human proteins.

3. www.genmab.com › aboutAbout | Genmab

   www.genmab.com › about

   • Cached

   About Genmab. Rooted in science and inspired by patients, we are committed to improving lives through innovative and differentiated antibody therapeutics. This is who we are. Our antibody therapeutics aim to transform the lives of people with cancer and other serious diseases. For our teams, this is the strongest possible motivation to come to ...

4. Top Stories

   • 

     GlobalData on MSN.com

     Genmab acquires biotechnology company ProfoundBio in $1.8bn deal

     1 week ago

   • 

     Business Insider

     What 9 Analyst Ratings Have To Say About Genmab

     1 week ago

   • YAHOO!Finance

     Genmab Completes Acquisition of ProfoundBio

     Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.

     1 week ago

   • Business Insider

     Genmab’s Buy Rating Affirmed by Promising Epcoritamab Trials and Regulatory Milestones

     Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report), retaining the price target of

     1 week ago

   • YAHOO!Finance

     Transactions in Connection with Share Buy-back Program

     On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16,

     2 days ago

   View all

5. Videos

   • 

     5:01

     youtube.com

     Antibody Architects

     Mar 6, 2023

     2.2K Views

   • 

     3:49

     youtube.com

     Genmab Receives 2021 Corporate Achievement Award from CancerCare

     May 14, 2021

     951 Views

   • 

     1:5:07

     youtube.com

     Genmab GMAB Q3 2023 Earnings Call & Presentation

     Dec 30, 2023

     76 Views

   View all

6. ir.genmab.com › news-releases › news-release-detailsGenmab Completes Acquisition of ProfoundBio - Genmab A/S

   ir.genmab.com › news-releases › news-release-details

   • Cached

   May 21, 2024 · Company Announcement. Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash. Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms.

7. finance.yahoo.com › news › genmab-completesGenmab Completes Acquisition of ProfoundBio - Yahoo Finance

   finance.yahoo.com › news › genmab-completes

   • Cached

   May 21, 2024 · GNMSF. Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash. Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart ...

8. People also ask

   What does Genmab do?

   • of antibody-based treatments Join our mission to improve the lives of patients medicines, research findings, and more. Genmab is a biotech company that creates antibody-based treatments for cancer and other serious diseases.

   Transforming the Future of Antibody-Based Cancer Treatment | Genmab …

   www.us.genmab.com/

   See all results for this question

   Where is Genmab based?

   • The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan.

   Genmab - Wikipedia

   en.wikipedia.org/wiki/Genmab

   See all results for this question

   Who is Genmab A/S?

   • Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.

   Genmab - Wikipedia

   en.wikipedia.org/wiki/Genmab

   See all results for this question

   When will Genmab update its guidance?

   • Genmab expects to update its guidance no later than in connection with its second quarter 2024 earnings. Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics.

   Genmab Completes Acquisition of ProfoundBio - Genmab A/S

   ir.genmab.com/news-releases/news-release-details/genmab-completes-acquisition-profoundbio

   See all results for this question